Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,208.7 Cr
verified against source
Revenue YoY
41%
reported change
EBITDA
₹298.2 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gland Pharma reported consolidated revenue of INR 1,209 crore for Q1 FY24, up 41% YoY, driven by the Cenexi acquisition (37% contribution) and 4% base business growth. EBITDA stood at INR 298 crore (25% margin), while PAT declined 15% to INR 194 crore due to higher depreciation and forex losses. Base business EBITDA margin remained healthy at 30%. U.S. sales grew 23% QoQ but declined 8% YoY, with 23 product launches including 15 relaunches from exited customers. Cenexi contributed INR 321 crore revenue in two months with 76% gross margin. Management expects sequential U.S. growth and gradual Cenexi margin improvement over 1-2 quarters. Key risk: integration challenges at Cenexi may delay synergy realization.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects steady sequential growth in U.S. revenue, with no decline anticipated.
- Cenexi EBITDA margins are expected to improve in the next 1-2 quarters through operational efficiencies.
- Enoxaparin sales are expected to pick up from next quarter as inventory rationalization ends.
- Total product launches in FY24 will be higher than normal due to relaunches, exceeding 40.
Risks flagged
- Integration of Cenexi may face operational challenges, delaying synergy realization and margin improvement.
- Aggressive pricing by Chinese players in injectables could pressure margins, though management sees recent stabilization.
- Enoxaparin sales recovery is critical for U.S. growth; any further delays could impact revenue.
- Annual four-week summer shutdown at Cenexi may temporarily affect revenue and margins in Q2.
Key quotes
- We have started the financial year on a positive note. The first quarter has demonstrated the same.
- The opportunity is to make it more efficient and reduction of costs are plenty.
- It's not that we're exiting, it's just that we're trying to be more selective in selling now while we work on improving the costs.
Research modules